Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands, comments on the improving cure rates for patients with Hodgkin lymphoma, highlighting the need for improved treatment regimens for older patients and the potential role of brentuximab vedotin and PD-1 inhibitors, as well as the need to improve the balance between efficacy and toxicity. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.